It is always an absolute privilege working with Iain Looking forward to his stint as @eular_org President...his track record suggests there will be some innovations ahead! @Racegbn @iiiglasgow @UofGMVLS @imidbio https://t.co/932Iz9kayV

• Maria Sokolova on Twitter: "An inspirational story of a great career by Ia…

EULAR HIGHLIGHTS. Ixekizumab beats adalimumab in PsA on combined end pt of skin + joints due to high skin response #EULAR2019 @RheumNow

EULAR Highlights. 2 new JAKs presented more RA data. Upadacitinib and Filgotinib. Safety of JAKs in meta-analysis -no new safety signals. Tofacitinib use in Corrona = TNFI except slightly more shingles. 7yr Baricitinib data good - no VTE in LTE #EULAR2019 @RheumNow

Eular highlights. RA guidelines still mostly like before - all MOA drugs ok after MTX and still taper if sustained remission. I think don't fully D/C all background Rx in most #EULAR2019 @RheumNow

Eular highlights. Don't forget aerobic supervised exercise to be prescribed in Axial SpA #EULAR2019 @RheumNow

Comparison of high and low iris acid levels in a large cohort of gout patients shows high SUA associated with more comorbidities and CKD, more colchicine & indocin use. #EULAR2019 SAT0435 https://t.co/FvUU4Q6Ky9

Dr. Peter Lipsky - 1 Million #Gout Patients & who cares for them. SAT0435 #EULAR2018 https://t.co/WfFR4tRf2p

• https://youtu.be/LxaF4KcCamA

A very productive Mentor Mentee meeting with the best mentors and best mentees @EMEUNET #EULAR19 #Madrid https://t.co/nLQkdnK0u3

@drdavidliew @OrphaLung @TobyMMaher @RheumNow See @RheumILD! We love Ritux!

Eular highlights? SSc trials near misses for efficacy. Abatacept v placebo in early diffuse scleroderma had begun primary outcome for skin but positive composite measure of response (CRISS) TCZ beg on skin but nearly significant; maybe less lung progression #EULAR2019 @RheumNow

Eular highlights SLE Rx Belimumab in largest SLE RCT is safe. Ustikinumab decreases interferon in SLE- Eploratory results from + RCT. Maybe blood levels of hydroxychloroquine may reduce Retinopathy by decreasing dose if high and detect adherence if too low #EULAR2019 @RheumNow

Eular highlights in scleroderma. Nintedanib + for SSc ILD. Positive correlations of combined response in SSc measure and PROs in RCT exploratory analysis of Lenabusum a cannabinoid receptor agonist, maybe riociguat helps Raynauds and digital ulcers #EULAR2019 @RheumNow

Eular highlights Sjögren's syndrome. Maybe new Rx pathway of small early phase RCT with RSLV-132 via toll like receptor 8 acting on interferon - reducing fatigue. Too early to know. #EULAR2019 @RheumNow

Benefits of #physicalactivity in #rheumatoidarthritis ➡️Disease related outcomes ➡️Systemic outcomes ➡️Financial costs via @NoreleeK #EULAR2019 #Exercise #arthritis https://t.co/5vnKaPdAQB

Here's a 2 min snapshot of #physicalactivity uptake at #EULAR2019 ➡️88% (23) used #escalator ➡️12% (3) used #stairs ➡️87% (20) on escalator stood still ➡️13% (3) walked on escalator Well done all who used stairs!👍🏽 Good use of facilities & opportunities https://t.co/7NgdOBtc1z